GLPwatch

The Related Metabolic Diseases and Treatments of Obesity.

Healthcare (Basel) · 2022

Last updated 2026-07-12

Obesity affects over 1 billion people worldwide and is linked to serious health issues like type 2 diabetes, liver disease, heart disease, and cancer. Treatments include lifestyle changes, FDA-approved medications like semaglutide and liraglutide, bariatric surgery for severe cases, and psychological support. Gut health, including microbes, also plays a role in managing obesity and related conditions.

AI summary of the abstract below.

JournalHealthcare (Basel), 2022
Citations117
Relative citation ratio12.30
NIH percentile98
Molecules
Conditions studied Obesity, Type 2 Diabetes, Cardiovascular Risk Reduction, Mash, Chronic Kidney Disease, Obstructive Sleep Apnea, Pcos

Abstract

Obesity is a chronic disease characterized by the abnormal or excessive accumulation of body fat, affecting more than 1 billion people worldwide. Obesity is commonly associated with other metabolic disorders, such as type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular diseases, chronic kidney disease, and cancers. Factors such as a sedentary lifestyle, overnutrition, socioeconomic status, and other environmental and genetic conditions can cause obesity. Many molecules and signaling pathways are involved in the pathogenesis of obesity, such as nuclear factor (NF)-κB, Toll-like receptors (TLRs), adhesion molecules, G protein-coupled receptors (GPCRs), programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1), and sirtuin 1 (SIRT1). Commonly used strategies of obesity management and treatment include exercise and dietary change or restriction for the early stage of obesity, bariatric surgery for server obesity, and Food and Drug Administration (FDA)-approved medicines such as semaglutide and liraglutide that can be used as monotherapy or as a synergistic treatment. In addition, psychological management, especially for patients with obesity and distress, is a good option. Gut microbiota plays an important role in obesity and its comorbidities, and gut microbial reprogramming by fecal microbiota transplantation (FMT), probiotics, prebiotics, or synbiotics shows promising potential in obesity and metabolic syndrome. Many clinical trials are ongoing to evaluate the therapeutic effects of different treatments. Currently, prevention and early treatment of obesity are the best options to prevent its progression to many comorbidities.

Verbatim abstract via PubMed 36141228 ↗